07-05-2025
First Automated Insulin System With 1-Year Sensor to Debut
A new partnership had led to the development of the first-ever automated insulin delivery (AID) system that incorporates a 1-year glucose sensor.
Sequel Med Tech, LLC and Senseonics have teamed up to feature the 1-year implantable Eversense 365 continuous glucose monitor (CGM) as a component of the twiist AID, which was cleared by the US Food and Drug Administration (FDA) in March 2024. In May 2024, the FDA deemed the Eversense to be compatible for use with insulin pumps, as are other CGM brands.
The twiist AID is approved for people aged 6 years or older with type 1 diabetes. However, the Eversense indication is for those aged 18 years or older, so that applies to the system as a whole.
The Eversense sensor is implanted subcutaneously into the upper arm by a healthcare professional, with the 1-year rechargeable transmitter worn above it. The sensor requires a once-weekly fingerstick calibration. The twiist insulin pump is reusable for up to 3 years, with a 300-unit reservoir that is replaced every 3 days with infusion set changes.
The twiist AID system is the first to directly measure the volume of microdosed insulin. The system is powered by the twiist Loop algorithm, which was based on the open-source Tidepool Loop. It automatically adjusts basal insulin delivery based on real-time readings from the sensor and predicted glucose levels.
The twiist system is set to be available in select areas of the United States during the second quarter of 2025.
